PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTX) (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell ...
Abstract Highlights Rinzimetostat is a potent and highly selective next-generation allosteric PRC2 inhibitor targeting the EED subunit that has demonstrated potential best-in-class efficacy and safety ...
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results